Search alternatives:
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), awd decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
n decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), awd decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
n decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
521
Fli-1 directly activates miR-17-92 promoter and contributes to miR-17 and miR-20a expression in NN10#5 cells.
Published 2012“…<p>A: NN10#5 cells have been cultured for two days in absence or presence of Dox used to induce Fli-1 knock-down before analysis. …”
-
522
-
523
-
524
Supplementary Material for: Use of the Myocardial Performance Index in Decreased Fetal Movement Assessment: A Case-Control Study
Published 2017“…<p><b><i>Objectives:</i></b> To determine whether there are any fetal cardiac function changes, as measured by the myocardial performance index (MPI), in pregnancies complicated by decreased fetal movement (DFM). <b><i>Methods:</i></b> We performed a prospective cross-sectional case-control study of 50 DFM and 50 uncomplicated third-trimester pregnancies matched within 2 gestational weeks. …”
-
525
-
526
Significant decrease of SMAD4 protein in DBA iPSCs.
Published 2015“…<p>DBA iPSCs (labelled as “<i>RPS19/RPL5</i> mutant” or “<i>RPS19/RPL5</i> mutant-”), the corrected DBA cells (expressing a WT version of the mutated gene, <i>RPL5</i> or <i>RPS19</i>, labelled as “<i>RPS19/RPL5</i> mutant <i>RPS19/RPL5</i>” or “corrected <i>RPS19/RPL5</i> mutant”) and the control GFP cells (expressing GFP, labelled as “<i>RPS19/RPL5</i> mutant GFP”) were cultured and the nuclear and cytoplasmic protein was extracted from iPSCs for western blot analysis, and RNA for q-PCR analysis. …”
-
527
Hedgehog signaling is decreased in <i>Foxa1</i>;<i>Foxa2</i> double knockouts.
Published 2013“…<i>Ptch1</i> expression was decreased in the tail of <i>Foxa1</i>;<i>Foxa2</i> double mutants (P) compared to control (M), <i>Foxa1</i> null (N) and <i>Foxa2</i> mutants (O). …”
-
528
Expanding Three-Coordinate Gold(I) Anticancer Agent Chemical Space
Published 2025“…The complexes demonstrated submicromolar cytotoxic activity against human breast cancer cells MDA-MB-231 or MDA-MB-468 with IC<sub>50</sub>’s in the range of 0.4–5.0 μM. Complex <b>2e</b> shows high potency in vitro and decreases 3D-breast cancer mammosphere viability. …”
-
529
-
530
-
531
-
532
-
533
-
534
CNP decrease mitochondrial membrane potential and induce mitochondrial fragmentation in melanoma cells.
Published 2020“…<p>A, 300 μM CNP (4 h) significantly decreased mitochondrial membrane potential in A375 cells, but not in melanocytes, indicated by changes of TMRM dependent fluorescence in mitochondria. …”
-
535
Decrease in Vitamin D Status in the Greenlandic Adult Population from 1987–2010
Published 2014“…A sub-sample (n = 330) donated a blood sample in 1987 which allowed assessment of time trends in vitamin D status.…”
-
536
-
537
Drugs which cluster on the 'anxiolytic' group decrease 5-HT turnover in the brain.
Published 2014“…A negative correlation is found between the decrease in serotonin turnover and the increase in time on white produced by a drug (r<sup>2</sup> = 0.5688, p = 0.0073).…”
-
538
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
539
-
540